Atea Pharmaceuticals Inc expected to post a loss of 58  cents a share - Earnings Preview

Atea Pharmaceuticals

07/05/2022 03:03

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 9. 
    * The Boston Massachusetts-based  company is expected to
report  a
94.9% decrease in revenue to $3.333 million from $65.99 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Atea
Pharmaceuticals Inc
is for a loss of 58 cents per share. For the same quarter last
year, the company reported earnings of 34 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $7.5​, above​ its last closing price
of $5.52. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.01       0.17       1.34      Beat    704
 Sep. 30 2021  -0.12       -0.05      -0.34     Missed  -547.6
 Jun. 30 2021  -0.10       0.01       0.02      Beat    300​
 Mar. 31 2021  -0.10       -0.05      0.34      Beat    718.2
 ​​Dec.                    0.16                         
 31 2020                                                
 Sep. 30 2020  -1.05       -1.05      -1.74     Missed  -64.9​
 This summary was machine generated May 7 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated